Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,897
datasets available to search
ShareScore release 0.9.0
Dataset results
2,897 results for “adjuvants”
A fungal-derived adjuvant amplifies the antitumoral potency of BCG
<p>A repository of data for the mouse single-cell multiome (RNA+ATAC) dataset of lineage negative bone marrow samples pre- and post- treatment BCG or b-glucan treated mice.</p>
Data - Effect of electrolytes as adjuvants in GFP and LPS partitioning on aqueous two-phase systems: 1. Polymer-polymer systems
<p><strong>Overview</strong></p> <p>The production of recombinant biopharmaceuticals is highly dependent of a proper choice of the downstream processing stages. Particularly, the purification that must ensure that all the endotoxins (lipopolysaccharide - LPS) are efficiently removed from the final product. This dataset contains the raw data and statistical analysis for the research entitled - "Effect of electrolytes as adjuvants in GFP and LPS partitioning on aqueous two-phase systems: 1. Polymer-polymer systems". </p> <p><strong>Info</strong></p> <p>ANOVA_Turkey_Sub.R <- code for ANOVA analysis in R statistic 3.3.3 <br> glm.R <- code for GLM analysis in R statistic 3.3.3<br> K&REC_LPS_PEG_NaPA.xlsx <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) and recover (REC) for ANOVA analysis<br> K&REC_LPS_PEG_NaPA_K.docx <- File with ANOVA result of partition coefficient (K) for GFP<br> K&REC_LPS_PEG_NaPA_REC.docx <- File with ANOVA result of recover (REC) for GFP <br> K_GFP_Pol_005.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in 0.05M salt assays <br> K_GFP_Pol_005.doc <- File with GLM analysis of GFP partition coefficient (K) in 0.05M salt assays <br> K_GFP_Pol_005_QQ.png <- Residual quantile plot of GLM analysis for partition coefficient (K) in 0.05M salt assays <br> K_GFP_Pol_025.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in 0.25M salt assays <br> K_GFP_Pol_025.doc <- File with GLM analysis of GFP partition coefficient (K) in 0.25M salt assays <br> K_GFP_Pol_025_QQ.png <- Residual quantile plot of GLM analysis for partition coefficient (K) in 0.25M salt assays <br> REC_GFP_Pol_005.csv <- File with raw values organized in a spreadsheet of GFP recover (REC) for GLM analysis in 0.05M salt assays <br> REC_GFP_Pol_005.doc <- File with GLM analysis of GFP recover (REC) in 0.05M salt assays <br> REC_GFP_Pol_005_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in 0.05M salt assays <br> REC_GFP_Pol_025.csv <- File with raw values organized in a spreadsheet of GFP recover (REC) for GLM analysis in 0.25M salt assays <br> REC_GFP_Pol_025.doc <- File with GLM analysis of GFP recover (REC) in 0.25M salt assays <br> REC_GFP_Pol_025_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in 0.25M salt assays <br> REM_LPS_PEG_NaPA.docx <- File with ANOVA result of LPS removal <br> REM_LPS_PEG_NaPA.xlsx <- File with raw values organized in a spreadsheet of LPS removal for ANOVA analysis<br> Stability_GFP_PEG_NaPA.docx <- File with ANOVA result of GFP stability<br> Stability_GFP_PEG_NaPA.xlsx <- File with raw values organized in a spreadsheet of GFP stability results for ANOVA analysis</p> <p>REM_LPS_Pol_005.csv <- File with raw values organized in a spreadsheet of LPS removal (REM) for GLM analysis in 0.05M salt assays <br> REM_LPS_Pol_005.doc <- File with GLM analysis of LPS removal (REM) in 0.05M salt assays <br> REM_LPS_Pol_005_QQ.png <- Residual quantile plot of GLM analysis of LPS removal (REM) in 0.05M salt assays <br> REM_LPS_Pol_025.csv <- File with raw values organized in a spreadsheet of LPS removal (REM) for GLM analysis in 0.25M salt assays <br> REM_LPS_Pol_025.doc <- File with GLM analysis of LPS removal (REM) in 0.25M salt assays <br> REM_LPS_Pol_025_QQ.png <- Residual quantile plot of GLM analysis of LPS removal (REM) in 0.25M salt assays</p> <p>K_GFP_Pol_025_NaCl_Li2SO4.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in 0.25M salt assays comparing NaCl and Li2SO4 effect <br> K_GFP_Pol_025_NaCl_Li2SO4.doc <- File with GLM analysis of GFP partition coefficient (K) in 0.25M salt assays comparing NaCl and Li2SO4 effect <br> K_GFP_Pol_025_NaCl_Li2SO4_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in 0.25M salt assays comparing NaCl and Li2SO4 effect </p> <p>REM_LPS_Pol_KI_0.05_vs_0.25.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in KI assays comparing salt concentration effect <br> REM_LPS_Pol_KI_0.05_vs_0.25.doc <- File with GLM analysis of GFP partition coefficient (K) in KI assays comparing salt concentration effect<br> REM_LPS_Pol_KI_0.05_vs_0.25_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in KI assays comparing salt concentration effect<br> REM_LPS_Pol_KNO3_0.05_vs_0.25.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in KNO3 assays comparing salt concentration effect <br> REM_LPS_Pol_KNO3_0.05_vs_0.25.doc <- File with GLM analysis of GFP partition coefficient (K) in KNO3 assays comparing salt concentration effect<br> REM_LPS_Pol_KNO3_0.05_vs_0.25_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in KNO3 assays comparing salt concentration effect<br> REM_LPS_Pol_Li2SO4_0.05_vs_0.25.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in Li2SO4 assays comparing salt concentration effect <br> REM_LPS_Pol_Li2SO4_0.05_vs_0.25.doc <- File with GLM analysis of GFP partition coefficient (K) in Li2SO4 assays comparing salt concentration effect<br> REM_LPS_Pol_Li2SO4_0.05_vs_0.25_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in Li2SO4 assays comparing salt concentration effect<br> REM_LPS_Pol_NaCl_0.05_vs_0.25.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in NaCl assays comparing salt concentration effect <br> REM_LPS_Pol_NaCl_0.05_vs_0.25.doc <- File with GLM analysis of GFP partition coefficient (K) in NaCl assays comparing salt concentration effect <br> REM_LPS_Pol_NaCl_0.05_vs_0.25_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in NaCl assays comparing salt concentration effect</p> <p> </p> <p><strong>Annotation</strong></p> <p>12/12 - Concentration of 12% of each polymer PEG/NaPA</p> <p>16/16 - Concentration of 16% of each polymer PEG/NaPA</p> <p>P/N - PEG/NaPA</p> <p>10e4, 10e5, 10e6 - Concentration of LPS in scientific notation - 10000, 100000, 100000 EU/mL</p> <p>poly - Polymer</p> <p>salt - Salt concentration in the assay</p> <p>tsalt - Type of salt in the assay (NaCl, KNO3, KI and Li2SO4)</p> <p>lps - lipopolysaccharide</p> <p>K - GFP partition coefficient</p> <p>REM - LPS removal</p> <p>REC - GFP recover</p> <p>wo_salt - Assay without salt addition</p> <p><strong>Acknowledgements</strong></p> <p>The authors are grateful for financial support from FAPESP (São Paulo Research Foundation, Brazil) through the following projects: 2005/60159-7; 2007/51978-0; 2014/16424-7; and 2014/19793-3. The authors also acknowledge the support from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) through the process #0366/09-9 and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil).</p> <p><strong>Consider citing our work. </strong></p> <p>1. Work in progress...</p>
Data - Effect of electrolytes as adjuvants in GFP and LPS partitioning on aqueous two-phase systems: 2. Nonionic micellar systems
<p><strong>Overview</strong></p> <p>The production of recombinant biopharmaceuticals is highly dependent of a proper choice of the downstream processing stages. Particularly, the purification that must ensure that all the endotoxins (lipopolysaccharide - LPS) are efficiently removed from the final product. This dataset contains the raw data and statistical analysis for the research entitled - "Effect of electrolytes as adjuvants in GFP and LPS partitioning on aqueous two-phase systems: 2. Nonionic micellar systems". </p> <p><strong>Info</strong></p> <p>ANOVA_Turkey_Sub.R <- code for ANOVA analysis in R statistic 3.3.3 <br> glm.R <- code for GLM analysis in R statistic 3.3.3<br> K&REC_ORG_ANOVA.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) and recover (REC) for ANOVA analysis</p> <p>K_ORG_ANOVA.docx <- File with ANOVA result of partition coefficient (K) for GFP</p> <p>REC_ORG_ANOVA.docx <- File with ANOVA result of partition coefficient (REC) for GFP</p> <p>REM_LPS_ORG_ANOVA.csv <- File with raw values organized in a spreadsheet of LPS removal for ANOVA analysis</p> <p>REM_LPS_ORG_ANOVA.docx <- File with ANOVA result of removal of LPS</p> <p>Stability__ORG_ANOVA.csv <- File with raw values organized in a spreadsheet of GFP stability for ANOVA analysis</p> <p>Stability__ORG_ANOVA.docx <- File with ANOVA result of GFP stability</p> <p>K_ORG_glm_005.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in 0.05M salt assays </p> <p>K_ORG_glm_005.doc <- File with GLM analysis of GFP partition coefficient (K) in 0.05M salt assays </p> <p>K_ORG_glm_005_QQ.png <- Residual quantile plot of GLM analysis for partition coefficient (K) in 0.05M salt assays </p> <p>K_ORG_glm_025.csv <- File with raw values organized in a spreadsheet of GFP partition coefficient (K) for GLM analysis in 0.25M salt assays </p> <p>K_ORG_glm_025.doc <- File with GLM analysis of GFP partition coefficient (K) in 0.25M salt assays </p> <p>K_ORG_glm_025_QQ.png <- Residual quantile plot of GLM analysis for partition coefficient (K) in 0.25M salt assays </p> <p>REC_ORG_glm_005.csv <- File with raw values organized in a spreadsheet of GFP recover (REC) for GLM analysis in 0.05M salt assays</p> <p>REC_ORG_glm_005.doc <- File with GLM analysis of GFP recover (REC) in 0.05M salt assays </p> <p>REC_ORG_glm_005_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in 0.05M salt assays </p> <p>REC_ORG_glm_025.csv <- File with raw values organized in a spreadsheet of GFP recover (REC) for GLM analysis in 0.25M salt assays</p> <p>REC_ORG_glm_025.doc <- File with GLM analysis of GFP recover (REC) in 0.25M salt assays </p> <p>REC_ORG_glm_025_QQ.png <- Residual quantile plot of GLM analysis of GFP recover (REC) in 0.25M salt assays </p> <p>REM_ORG_glm_005.csv <- File with raw values organized in a spreadsheet of LPS removal (REM) for GLM analysis in 0.05M salt assays</p> <p>REM_ORG_glm_005.doc <- File with GLM analysis of LPS removal (REM) in 0.05M salt assays </p> <p>REM_ORG_glm_005_QQ.png <- Residual quantile plot of GLM analysis of LPS removal (REM) in 0.25M salt assays</p> <p>REM_ORG_glm_025.csv <- File with raw values organized in a spreadsheet of LPS removal (REM) for GLM analysis in 0.25M salt assays</p> <p>REM_ORG_glm_025.doc <- File with GLM analysis of LPS removal (REM) in 0.25M salt assays </p> <p>REM_ORG_glm_025_QQ.png <- Residual quantile plot of GLM analysis of LPS removal (REM) in 0.25M salt assays</p> <p> </p> <p><strong>Annotation</strong></p> <p>12/12 - Concentration of 12% of each polymer PEG/NaPA</p> <p>16/16 - Concentration of 16% of each polymer PEG/NaPA</p> <p>P/N - PEG/NaPA</p> <p>10e4, 10e5, 10e6 - Concentration of LPS in scientific notation - 10000, 100000, 100000 EU/mL</p> <p>poly - Polymer</p> <p>salt - Salt concentration in the assay</p> <p>tsalt - Type of salt in the assay (NaCl, KNO3, KI and Li2SO4)</p> <p>lps - lipopolysaccharide</p> <p>K - GFP partition coefficient</p> <p>REM - LPS removal</p> <p>REC - GFP recover</p> <p>wo_salt - Assay without salt addition</p> <p><strong>Acknowledgements</strong></p> <p>The authors are grateful for financial support from FAPESP (São Paulo Research Foundation, Brazil) through the following projects: 2005/60159-7; 2007/51978-0; 2014/16424-7; and 2014/19793-3. The authors also acknowledge the support from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) through the process #0366/09-9 and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil).</p> <p><strong>Consider citing our work. </strong></p> <p>1. Work in progress...</p>
Fig. 5 in An Agricultural Detergent as Co-Adjuvant for Entomopathogenic Fungi and Chlorpyrifos to Control Pseudococcus viburni (Hemiptera: Pseudococcidae)
Fig. 5. Mortality (%) of Pseudococcus viburni females to (A) chlorpyrifos alone, and (B) mixed with a nonlethal concentration of TS-2035.
Fig. 4 in An Agricultural Detergent as Co-Adjuvant for Entomopathogenic Fungi and Chlorpyrifos to Control Pseudococcus viburni (Hemiptera: Pseudococcidae)
Fig. 4. Mycelium growth of (A-C) Beauveria bassiana, and (D-F) Metarhizium anisopliae on Pseudococcus viburni females at 24, 72, and 172 h afer exposure.
Fig. 3 in An Agricultural Detergent as Co-Adjuvant for Entomopathogenic Fungi and Chlorpyrifos to Control Pseudococcus viburni (Hemiptera: Pseudococcidae)
Fig. 3. Mortality (%) of Pseudococcus viburni females to (A) Metarhizium anisopliae alone, and (B) mixed with a nonlethal concentration of TS-2035.
Fig. 1 in An Agricultural Detergent as Co-Adjuvant for Entomopathogenic Fungi and Chlorpyrifos to Control Pseudococcus viburni (Hemiptera: Pseudococcidae)
Fig. 1. Mortality (%) of Pseudococcus viburni females afer exposure to several concentrations of TS-2035.
Fig. 2 in An Agricultural Detergent as Co-Adjuvant for Entomopathogenic Fungi and Chlorpyrifos to Control Pseudococcus viburni (Hemiptera: Pseudococcidae)
Fig. 2. Mortality (%) of Pseudococcus viburni females to (A) Beauveria bassiana alone, and (B) mixed with a nonlethal concentration of TS-2035.
Geometry models of specimens: Micro-CT, Mechanical, and Histological Examination of the Effect of Local Adjuvants on Porcine Cortical Bone Following Intralesional Curettage of Bone Tumors.
<p>Bone samples for micro CT measurements and reconstructed bone geometry from micro CT data.</p>
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
ClinicalTrials.gov study NCT04762680. IPD Sharing: YES. Countries: 7. Publications: 2.
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
ClinicalTrials.gov study NCT00878709. IPD Sharing: YES. Countries: 40. Publications: 7.
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
ClinicalTrials.gov study NCT01682083. IPD Sharing: YES. Countries: 25. Publications: 9.
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
ClinicalTrials.gov study NCT01235962. IPD Sharing: YES. Countries: 26. Publications: 2.
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
ClinicalTrials.gov study NCT00490139. IPD Sharing: YES. Countries: 44. Publications: 7.
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
ClinicalTrials.gov study NCT03078751. IPD Sharing: YES. Countries: 1. Publications: 1.
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acr
ClinicalTrials.gov study NCT03447769. IPD Sharing: YES. Countries: 41. Publications: 1.
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
ClinicalTrials.gov study NCT03968419. IPD Sharing: YES. Countries: 12. Publications: 1.
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-
ClinicalTrials.gov study NCT00790036. IPD Sharing: UNDECIDED. Countries: 34. Publications: 1.
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
ClinicalTrials.gov study NCT03551626. IPD Sharing: YES. Countries: 23. Publications: 1.
Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
<p><em>Purpose:</em></p> <p>Ketogenic diets may positively influence cancer through pleiotropic mechanisms, but only a few small and short-term studies have addressed feasibility and efficacy in cancer patients. The primary goals of this study were to evaluate the feasibility and the sustained metabolic effects of a personalized well-formulated ketogenic diet (WFKD) designed to achieve consistent blood beta-hydroxybutyrate (<span>β</span>HB) >0.5 mM in women diagnosed with stage IV metastatic breast cancer (MBC) undergoing chemotherapy.</p> <p><em>Methods: </em></p> <p>Women (n = 20) were enrolled in a six-month two-phase, single-arm WFKD intervention (NCT03535701). Phase I was a highly-supervised, ad libitum, personalized WFKD, where women were provided with ketogenic-appropriate food daily for three-months. Phase II transitioned women to a self-administered WFKD with ongoing coaching for an additional three-months. Fasting capillary <span>β</span>HB and glucose were collected daily; weight, body composition, plasma insulin, and insulin resistance were collected at baseline, three- and six-months. </p> <p><em>Results:</em></p> <p>Capillary <span>β</span>HB indicated women achieved nutritional ketosis (Phase I mean: 0.8 mM (n = 15); Phase II mean: 0.7 mM (n = 9)). Body weight decreased 10% after three-months, primarily from body fat. Fasting plasma glucose, plasma insulin, and insulin resistance also decreased significantly after three-months (p < 0.01), an effect that persisted at six-months.</p> <p><em>Conclusions</em>:</p> <p>Women diagnosed with MBC undergoing chemotherapy can safely achieve and maintain nutritional ketosis, while improving body composition and insulin resistance, out to six-months.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.